Clinical Trials

Several Phase 1 clinical trials sponsored by major pharmaceutical entities—including Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Agile Therapeutics, and ViiV Healthcare—have evaluated the pharmacokinetic interactions and profiles associated with this compound. These studies investigated healthy volunteers as well as patient populations with Human Immunodeficiency Virus infection, Type 2 Diabetes Mellitus, and Hepatitis C Virus infection. Although the majority of these evaluations reached completed recruitment status, a clinical trial was suspended prior to completion.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01498861 Completed
Infection Human Immunodeficiency Virus
ViiV Healthcare|Shionogi|GlaxoSmithKline
2011-12 Phase 1
NCT01458210 Completed
Diabetes Mellitus Type 2
Eli Lilly and Company
2011-10 Phase 1
NCT01063023 Completed
Hepatitis C Virus
Bristol-Myers Squibb
2010-01 Phase 1
NCT01243580 Completed
Healthy
Agile Therapeutics
2009-08 Phase 1
NCT00901290 Suspended
Pharmacokinetics
AstraZeneca
2009-05 Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Cyclen product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a macrocyclic ligand, cyclen selectively binds metal cations to form stable coordination complexes, inhibiting downstream cation-dependent enzyme functions and biochemical signaling pathways within host cells. The resulting alteration of cellular ion homeostasis and biochemical activity underlies its biological profile, providing clinical relevance for evaluating drug safety, efficacy, and pharmacokinetic properties in patients with Human Immunodeficiency Virus infection, Type 2 Diabetes Mellitus, or Hepatitis C Virus.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.